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speciﬁc markers, e.g. growth hormone (GH) and insulin-like
growth factor (IGF-I)] and to compare the results of the 22-item
[8 physical and 14 psychological] Acromegaly Quality-of-Life
questionnaire [ACROQOL] and Short Form-36 Health Survey
[SF-36] in this population. Some of data collected will support
also the ongoing validation of ACROQOL questionnaire.
METHODS: This is the largest European multinational, open,
non-comparative, single evaluation, observational trial evaluat-
ing the HRQOL of patients with acromegaly treated with San-
dostatin® LAR®. This preliminary analysis presents interim
results from 208 Italian and 71 Spanish patients. Recruitment is
ongoing in England, France, Germany, Greece, Portugal, and
Turkey. A total of more than 500 patients are expected. GH and
IGF-I levels were measured within two months of completion 
of the questionnaires and sociodemographic data were also
recorded. Multivariate analyses were used to explore relation-
ship between HRQOL score and clinical and sociodemographic
variables. RESULTS: From this preliminary analysis, there was
no apparent relationship between HRQOL and sociodemo-
graphic variables; and no correlation with levels of GH or IGF-
I. There was a marked correlation between ACROQOL and
physical component score of SF-36, but less signiﬁcant correla-
tion between ACROQOL and mental component score. The
overall impact of acromegaly on HRQOL in patients treated
with Sandostatin® LAR® has not yet been analysed. CON-
CLUSIONS: ACROQOL may be a more descriptive measure of
HRQOL in the acromegaly population than the SF-36. In terms
of the SF-36, there was a superior correlation between the phys-
ical function component and ACROQOL than with the mental
component score, suggesting that the ACROQOL is more sensi-
tive to the psychological impact of the disease.
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OBJECTIVES: To investigate whether long-term GH replace-
ment in GH deﬁcient adults results in improvements in PRO and
HCU in comparison with Dutch population data. METHODS:
Analyses were performed using data from KIMS (Pﬁzer Interna-
tional Metabolic Database). Data were available for 164 Dutch
patients (78 men) for the ﬁrst year of treatment, whereas 2 and
3-year follow-up data were available for 107 and 62 patients
respectively. Quality of life (QoL) was assessed using the Not-
tingham Health Proﬁle (NHP) and disease-speciﬁc QoL-AGHDA
questionnaire. HCU data were obtained with the Patient Life 
Situation Form (PLSF). Statistical analyses were performed with
repeated measurements technique (all values presented as mean
± SEM or mean (95% CI). Normative data for the QoL-AGHDA
questionnaire are currently being collected and will be compared
with patient data. RESULTS: Both QoL measures showed a sig-
niﬁcant sustained improvement over the 3-year treatment period
(from 7.5 ± 0.55 to 5.0 ± 0.59 for NHP, from 10 ± 0.5 to 6.8 ±
0.7 for AGHDA). Data collected with the PLSF showed a sus-
tained subjective improvement in personal well-being for more
than two-third of patients. There was a signiﬁcant decrease from
the previous years in the number of visits to the doctor (from
7.1 (5.7–8.8) to 2.7 (1.7–4.3)), days in hospital (from 5.1
(3.0–8.6) to 1.7 (0.3–8.6)) and days of sick leave (from 39
(0–120) to 1.9 (0–10)) during GH therapy. These data in com-
parison with the average number of visits to the doctor in
2004–5.3 (Source, CBS, 2005), the average number of hospital
days in 2003–4.6 days (Source, Prismant, 2005) and average
number of sick days in 2003 for the Dutch working population—
14.7 (Source, CBS, 2005) showed normalization of HCU CON-
CLUSION: Data obtained conﬁrm that GH replacement therapy
results in a sustained long-term improvement in PRO and nor-
malization of HCU in The Netherlands.
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OBJECTIVES: To evaluate the timing and degree of symptom
relief with rabeprazole in a real life setting of patients with
gastro-oesophageal reﬂux disease (GERD). METHODS: A
prospective, multi-centre, observational study was conducted in
which Canadian general practitioners (n = 115) prescribed
rabeprazole to adults with GERD. Subjects had to be newly diag-
nosed or demonstrate insufﬁcient control on their current PPI,
H2-antagonist and/or antacid and not have used rabeprazole
previously. At the baseline ofﬁce visit (Day 0), physicians col-
lected demographic and clinical history data. Subjects were 
prescribed rabeprazole (2 ¥ 10mg daily) and sent home with a
seven-day diary to record symptom severity and symptom
control. Subjects also completed a Global Symptom Rating on
Day 7 with improvement deﬁned as equal to as or greater than
1 point change in severity rating. RESULTS: Of the 312 subjects
who reported taking rabeprazole on Day 0, more than half were
over 50 years of age and 56% female. The number of subjects
reporting baseline Daytime Heartburn (D-HB), baseline Night-
time Heartburn (N-HB), and Regurgitation (R) were 245, 230
and 194 respectively. 63% of D-HB, 73% of N-HB and 72% of
R reported improvement within the ﬁrst 2 days of therapy. Of
the subjects experiencing improvement during the ﬁrst two days
of therapy, 83% of D-HB, 83% of N-HB and 82% of R main-
tained or further improved symptoms to the end of the study.
Overall, the majority of patients (76%) indicated marked (56%)
or moderate (20%) improvement for the onetime Global
Symptom Rating score on Day 7. CONCLUSIONS: Rabeprazole
demonstrated a high level of effectiveness within the ﬁrst two
days of therapy, which was maintained in subjects with a pro-
longed history of GERD, including those with prior PPI treat-
ment. The results of this real world study provided valuable
information on the true efﬁcacy of rabeprazole.
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OBJECTIVES: To evaluate cost-effectiveness and budget impact
of short and long-term lamivudine antiviral treatment for
chronic hepatitis type B (CHB) in Taiwan. METHODS: A
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Markov model was constructed to analyse CHB patients’ life
expectancy (LE) of no antiviral treatment versus 18-month, 36-
month, and unrestricted duration of lamivudine treatment, and
their associated reimbursement cost from Taiwan National
Health Insurance (TNHI) perspective. Disease progression, 
clinical effectiveness and patient population information were
obtained from systematic review of published studies. Costs of
medication, diagnostics, physician’s fees, and hospitalization
were included. Incremental cost-effectiveness ratios (ICERs)
compared to disease progression without antiviral treatment
were derived. The annual cost of lamivudine treatment was
based on a 10% recruitment rate from 120,000 eligible 30-year-
old CHB patients. All costs and health outcomes were discounted
at 3%. RESULTS: CHB without antiviral treatment results in LE
loss of 21.7 years for 30-year-old CHB patients. Lamivudine
used for 18-months, 36-months, and unrestricted treatment
duration could increase LE by 2.5, 4.0, and 5.1 years respec-
tively; continuing treatment in patients with cirrhosis could
increase LE by 10.2 years. Expected lifetime costs to the TNHI
for no antiviral treatment were US$12,854 per patient. Incre-
mental costs of using lamivudine for 18-month, 36-month, and
unrestricted duration were US$697, US$1031 and US$1278
respectively. ICERs for 18-month, 36-month, and unrestricted
were US$575.7, US$542.5, and US$530.3; and US$1820.4 for
treating cirrhotic patients. Expected maximal annual budget for
lamivudine was US$13.0m, US$15.3m, and US$15.3m for 18-
month, 36-month, and unrestricted respectively; and US$32.3m
for continuing treatment in cirrhotic patients. CONCLUSIONS:
CHB results in marked LE loss to patients. Lamivudine treat-
ment notably improves LE. The effectiveness of lamivudine
increased with increased treatment duration and when contin-
ued in cirrhotic patients. Long-term antiviral treatment of CHB
with lamivudine is a cost effective strategy in Taiwan with a man-
ageable impact on budgets.
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COST-EFFECTIVENESS OF HELICOBACTER PYLORI TESTING
FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK
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OBJECTIVES: To assess the cost-effectiveness of three tests for
HP detection in adults and develop decision analysis models to
compare “test—no test” strategies for the treatment of persistent
dyspepsia. METHODS: Two decision analytic models were con-
structed and analysed from the perspective of the health service.
The ﬁrst model was a simple decision tree of three types of HP
test, allowing for true and false test results, with the ‘number of
true outcomes’ as the measure of effectiveness. Tests considered
were the serological test, the C-urea breath test and the mono-
clonal faecal antigen test. The second model was based on pub-
lished guidelines for managing dyspepsia and procedures in
secondary care. Measures of effectiveness for the second model
include numbers in each end state, number of endoscopies per-
formed, and number of HP eradication treatments given inap-
propriately and the extent of wasted resources consumed. Data
used to furnish the models were gathered from the literature and
available published costs. RESULTS: The monoclonal faecal
antigen test was the most cost effective solution with an ICER
of £2 per additional true outcome, but was highly dependent on
the sensitivity and speciﬁcity of the serological test. The stool test
and the breath test either dominate or are relatively cost effec-
tive in relation to the serological test unless the speciﬁcity of the
serological test exceeds 0.93. The stool test either dominates or
is relatively cost effective in relation to serological test up to a
cost of £18.67 per stool test. Preliminary results from the second
model suggest that the decision is highly dependent on values
attached to the variables in the model, especially in relation to
costs of treatment and costs associated with malignancy. CON-
CLUSION: In the UK, the faecal antigen test is a cost effective
solution to testing for HP in dyspepsia patients.
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TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN,
A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN
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OBJECTIVES: To clarify whether the therapy of liver cirrhosis
with silymarin shows a higher cost-effectiveness than a treatment
without from of the third party payerxs perspective.
METHODS: To calculate the incremental cost-effectiveness
based upon a clinical study, the liver-related mortality rates of
patients with liver cirrhosis after four years, treated with or
without silymarin, were compared. Adverse effects (AE) and
adverse drug reactions (ADR) were also be considered. Com-
parative parameters were costs, effectiveness and tolerability of
both alternatives. Costs were generated by the drug therapy of
liver cirrhosis, medical care, and treatments of AE and ADR,
which were derived from previous studies and portrayed in a
core-model. The calculation of the model was performed by util-
ising the program DATA Professional. Two sensitivity-analyses
were conducted. RESULTS: For liver-related mortality total costs
of €5467 for silymarin and €3333 without silymarin were gen-
erated. The effectiveness-adjusted costs were calculated at €5970
for silymarin and €4009 for treatment without silymarin. This
entails that for the longer survival time of 9.12 months, incre-
mental costs of €1961 were calculated per silymarin patient.
However, as an effect, less AEs occurred and longer survival of
patients could be achieved with silymarin treatment of liver cir-
rhosis. CONCLUSION: With silymarin treatment of liver cir-
rhosis less AEs and longer survival of patients could be achieved.
By considering the concept of prolonged life, cost amounting to
€2580 was estimated per life year gained (lyg).
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OBJECTIVES: Peginterferon alfa-2b (12KD)/ribavirin (PEG2b)
has been shown to produce a higher rate of sustained virologi-
cal response (SVR) than non-pegylated combination therapy
(non-PEG) in CHC, but the cost effectiveness of this improved
efﬁcacy has not been assessed in Brazil. METHODS: We devel-
oped a Markov model to describe the clinical history of CHC in
which the cohorts of hepatitis C virus (HCV) patients received
PEG2B or non-PEG for either 48 or 24 weeks according to geno-
type and liver histology and were followed for their expected life-
time. The reference patient was a 30-year-old male with CHC
without cirrhosis. The SVRs to PEG2B and non-PEG were 48%
and 34% for HCV genotype 1 and 88% and 80% for non-1,
respectively. Quality of life for each health state was based on
literature. Costs for each health state were based on three Delphi
panels, one with hepatologists, one with intensivists and another
with oncologists. Costs in 2004 reais and beneﬁts were dis-
counted at 3%. RESULTS: In HCV genotype 1, PEG2B increases
life expectancy (LY) by 1.79 years and quality adjusted life
expectancy (QALY) by 0.82 years compared to non-PEG. The
